

Miles Parkes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5490720/publications.pdf>

Version: 2024-02-01

150
papers

43,837
citations

15495

65
h-index

11047

137
g-index

159
all docs

159
docs citations

159
times ranked

48496
citing authors

#	ARTICLE	IF	CITATIONS
1	Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. <i>Nature</i> , 2007, 447, 661-678.	13.7	8,895
2	Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. <i>Nature</i> , 2012, 491, 119-124.	13.7	4,038
3	Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. <i>Nature Genetics</i> , 2008, 40, 955-962.	9.4	2,422
4	Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. <i>Nature Genetics</i> , 2010, 42, 1118-1125.	9.4	2,284
5	Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. <i>Autophagy</i> , 2008, 4, 151-175.	4.3	2,064
6	Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. <i>Nature Genetics</i> , 2015, 47, 979-986.	9.4	1,965
7	British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. <i>Gut</i> , 2019, 68, s1-s106.	6.1	1,353
8	Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. <i>Nature Genetics</i> , 2007, 39, 1329-1337.	9.4	1,298
9	Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. <i>Nature Genetics</i> , 2011, 43, 246-252.	9.4	1,201
10	Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. <i>Nature Genetics</i> , 2007, 39, 830-832.	9.4	1,063
11	Disease-Specific Alterations in the Enteric Virome in Inflammatory Bowel Disease. <i>Cell</i> , 2015, 160, 447-460.	13.5	1,036
12	Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. <i>Nature Genetics</i> , 2017, 49, 256-261.	9.4	943
13	Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. <i>Nature</i> , 2010, 464, 713-720.	13.7	737
14	Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. <i>Nature Genetics</i> , 2011, 43, 1066-1073.	9.4	698
15	Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. <i>Nature Genetics</i> , 1996, 14, 199-202.	9.4	682
16	Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. <i>Nature Genetics</i> , 2016, 48, 510-518.	9.4	617
17	Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. <i>Lancet, The</i> , 2016, 387, 156-167.	6.3	607
18	Meta-analysis and imputation refines the association of 15q25 with smoking quantity. <i>Nature Genetics</i> , 2010, 42, 436-440.	9.4	581

#	ARTICLE	IF	CITATIONS
19	New IBD genetics: common pathways with other diseases. <i>Gut</i> , 2011, 60, 1739-1753.	6.1	504
20	Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. <i>Nature Genetics</i> , 2009, 41, 1330-1334.	9.4	483
21	Fine-mapping inflammatory bowel disease loci to single-variant resolution. <i>Nature</i> , 2017, 547, 173-178.	13.7	473
22	Bayesian refinement of association signals for 14 loci in 3 common diseases. <i>Nature Genetics</i> , 2012, 44, 1294-1301.	9.4	469
23	Common variants at five new loci associated with early-onset inflammatory bowel disease. <i>Nature Genetics</i> , 2009, 41, 1335-1340.	9.4	459
24	Genetic insights into common pathways and complex relationships among immune-mediated diseases. <i>Nature Reviews Genetics</i> , 2013, 14, 661-673.	7.7	459
25	Proteins Encoded in Genomic Regions Associated with Immune-Mediated Disease Physically Interact and Suggest Underlying Biology. <i>PLoS Genetics</i> , 2011, 7, e1001273.	1.5	450
26	Predictors of anti-TNF treatment failure in anti-TNF-naïve patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 341-353.	3.7	431
27	Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. <i>Nature Genetics</i> , 2008, 40, 710-712.	9.4	403
28	High-density mapping of the MHC identifies a shared role for HLA-DRB1*01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis. <i>Nature Genetics</i> , 2015, 47, 172-179.	9.4	280
29	Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis. <i>Journal of Clinical Investigation</i> , 2011, 121, 4170-4179.	3.9	268
30	Genome-wide association study identifies distinct genetic contributions to prognosis and susceptibility in Crohn's disease. <i>Nature Genetics</i> , 2017, 49, 262-268.	9.4	250
31	Prevalence of CARD15/NOD2 Mutations in Caucasian Healthy People. <i>American Journal of Gastroenterology</i> , 2007, 102, 1259-1267.	0.2	249
32	HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2020, 158, 189-199.	0.6	249
33	British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. <i>Gut</i> , 2020, 69, 984-990.	6.1	232
34	Human SNP Links Differential Outcomes in Inflammatory and Infectious Disease to a FOXO3-Regulated Pathway. <i>Cell</i> , 2013, 155, 57-69.	13.5	200
35	Investigation of Crohn's Disease Risk Loci in Ulcerative Colitis Further Defines Their Molecular Relationship. <i>Gastroenterology</i> , 2009, 136, 523-529.e3.	0.6	198
36	Deep Resequencing of GWAS Loci Identifies Rare Variants in CARD9, IL23R and RNF186 That Are Associated with Ulcerative Colitis. <i>PLoS Genetics</i> , 2013, 9, e1003723.	1.5	185

#	ARTICLE	IF	CITATIONS
37	Negligible impact of rare autoimmune-locus coding-region variants on missing heritability. <i>Nature</i> , 2013, 498, 232-235.	13.7	184
38	IL23R Variation Determines Susceptibility But Not Disease Phenotype in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2007, 132, 1657-1664.	0.6	170
39	HLA-DQA1 and HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. <i>Nature Genetics</i> , 2014, 46, 1131-1134.	9.4	165
40	Exploring the genetic architecture of inflammatory bowel disease by whole-genome sequencing identifies association at ADCY7. <i>Nature Genetics</i> , 2017, 49, 186-192.	9.4	153
41	Association Between Variants of PRDM1 and NDP52 and Crohn's Disease, Based on Exome Sequencing and Functional Studies. <i>Gastroenterology</i> , 2013, 145, 339-347.	0.6	149
42	Defective ATG16L1-mediated removal of IRE1 β drives Crohn's disease-like ileitis. <i>Journal of Experimental Medicine</i> , 2017, 214, 401-422.	4.2	141
43	Anti-commensal IgG Drives Intestinal Inflammation and Type 17 Immunity in Ulcerative Colitis. <i>Immunity</i> , 2019, 50, 1099-1114.e10.	6.6	139
44	Mucosal genome-wide methylation changes in inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 2128-2137.	0.9	135
45	Genome-wide Association Scanning Highlights Two Autophagy Genes, <i>ATG16L1</i> and <i>IRGM</i> , as Being Significantly Associated with Crohn's Disease. <i>Autophagy</i> , 2007, 3, 649-651.	4.3	132
46	A blood-based prognostic biomarker in IBD. <i>Gut</i> , 2019, 68, 1386-1395.	6.1	132
47	Mobilisation of enterocyte fat stores by oral glucose in humans. <i>Gut</i> , 2003, 52, 834-839.	6.1	131
48	Association of Genetic Variants in <i>NUDT15</i> With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 773.	3.8	129
49	Somatic Evolution in Non-neoplastic IBD-Affected Colon. <i>Cell</i> , 2020, 182, 672-684.e11.	13.5	122
50	Use of sirolimus (rapamycin) to treat refractory Crohn's disease. <i>Gut</i> , 2008, 57, 1294-1296.	6.1	118
51	Cytokine gene polymorphisms in inflammatory bowel disease. <i>Gut</i> , 1996, 39, 705-710.	6.1	112
52	SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 218-224.	3.7	111
53	Systematic review: the use of mesalazine in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 841-855.	1.9	106
54	COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 342-352.	3.7	100

#	ARTICLE	IF	CITATIONS
55	Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders. <i>Nature Genetics</i> , 2021, 53, 1543-1552.	9.4	96
56	Crohn disease: A current perspective on genetics, autophagy and immunity. <i>Autophagy</i> , 2011, 7, 355-374.	4.3	94
57	Evidence for association of OCTN genes and IBD5 with ulcerative colitis. <i>Gut</i> , 2006, 55, 809-814.	6.1	90
58	Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 910-923.	1.9	87
59	The IBD2 Locus Shows Linkage Heterogeneity between Ulcerative Colitis and Crohn Disease. <i>American Journal of Human Genetics</i> , 2000, 67, 1605-1610.	2.6	85
60	Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 149-158.	0.6	85
61	Human keratin 8 mutations that disturb filament assembly observed in inflammatory bowel disease patients. <i>Journal of Cell Science</i> , 2004, 117, 1989-1999.	1.2	84
62	Association of ulcerative colitis with rare VNTR alleles of the human intestinal mucin gene, MUC3. <i>Human Molecular Genetics</i> , 1999, 8, 307-311.	1.4	74
63	Contribution of TNFSF15 gene variants to Crohn's disease susceptibility confirmed in UK population. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 733-737.	0.9	74
64	Susceptibility loci in inflammatory bowel disease. <i>Lancet</i> , The, 1996, 348, 1588.	6.3	72
65	NOX1 loss-of-function genetic variants in patients with inflammatory bowel disease. <i>Mucosal Immunology</i> , 2018, 11, 562-574.	2.7	71
66	Analysis of Germline GLI1 Variation Implicates Hedgehog Signalling in the Regulation of Intestinal Inflammatory Pathways. <i>PLoS Medicine</i> , 2008, 5, e239.	3.9	63
67	Two microbiota subtypes identified in irritable bowel syndrome with distinct responses to the low FODMAP diet. <i>Gut</i> , 2022, 71, 1821-1830.	6.1	63
68	Pooled Sequencing of 531 Genes in Inflammatory Bowel Disease Identifies an Associated Rare Variant in BTNL2 and Implicates Other Immune Related Genes. <i>PLoS Genetics</i> , 2015, 11, e1004955.	1.5	59
69	Genetic association between NLRP3 variants and Crohn's disease does not replicate in a large UK panel. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1387-1391.	0.9	56
70	Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 1313-1323.	1.9	55
71	Predicting Outcomes For Crohn's disease using a molecular biomarker (PROFILE): protocol for a multicentre, randomised, biomarker-stratified trial. <i>BMJ Open</i> , 2018, 8, e026767.	0.8	55
72	Personalised medicine in Crohn's disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 80-92.	3.7	55

#	ARTICLE	IF	CITATIONS
73	Contribution of the IL-2 and IL-10 genes to inflammatory bowel disease (IBD) susceptibility. <i>Clinical and Experimental Immunology</i> , 1998, 113, 28-32.	1.1	54
74	Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 150-161.	1.9	53
75	Genetics of inflammatory bowel disease: clues to pathogenesis. <i>British Medical Bulletin</i> , 2008, 87, 17-30.	2.7	51
76	Genetics of Inflammatory Bowel Disease. <i>Clinical Science</i> , 1998, 94, 473-478.	1.8	50
77	Gender-stratified analysis of DLG5 R30Q in 4707 patients with Crohn disease and 4973 controls from 12 Caucasian cohorts. <i>Journal of Medical Genetics</i> , 2007, 45, 36-42.	1.5	47
78	Evidence for inflammatory bowel disease of a susceptibility locus on the X chromosome. <i>Gastroenterology</i> , 2001, 120, 834-840.	0.6	46
79	Rare and functional SIAE variants are not associated with autoimmune disease risk in up to 66,924 individuals of European ancestry. <i>Nature Genetics</i> , 2012, 44, 3-5.	9.4	44
80	Dynamic immunoglobulin responses to gut bacteria during inflammatory bowel disease. <i>Gut Microbes</i> , 2020, 11, 405-420.	4.3	44
81	Evidence from Genetics for a Role of Autophagy and Innate Immunity in IBD Pathogenesis. <i>Digestive Diseases</i> , 2012, 30, 330-333.	0.8	42
82	Genome-wide association studies and Crohn's disease. <i>Briefings in Functional Genomics</i> , 2011, 10, 71-76.	1.3	41
83	Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn's disease: long-term outcomes for 11,928 patients in the UK inflammatory bowel disease bioresource. <i>Gut</i> , 2021, 70, 677-686.	6.1	41
84	The Impact of NOD2 Variants on Fecal Microbiota in Crohn's Disease and Controls Without Gastrointestinal Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 583-592.	0.9	40
85	Genetic variants in TNF- β but not DLG5 are associated with inflammatory bowel disease in a large United Kingdom cohort. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 178-184.	0.9	39
86	Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease. <i>Nature Communications</i> , 2020, 11, 995.	5.8	37
87	How Do We Predict a Patient's Disease Course and Whether They Will Respond to Specific Treatments?. <i>Gastroenterology</i> , 2022, 162, 1383-1395.	0.6	31
88	Analysis of the BTNL2 truncating splice site mutation in tuberculosis, leprosy and Crohn's disease. <i>Tissue Antigens</i> , 2007, 69, 236-241.	1.0	30
89	A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 421-430.	1.9	30
90	Generation of primary human intestinal T cell transcriptomes reveals differential expression at genetic risk loci for immune-mediated disease. <i>Gut</i> , 2015, 64, 250-259.	6.1	30

#	ARTICLE	IF	CITATIONS
91	Intestinal APCs of the endogenous nanomineral pathway fail to express PD-L1 in Crohn's disease. <i>Scientific Reports</i> , 2016, 6, 26747.	1.6	30
92	Complex insertion/deletion polymorphism in NOD1 (CARD4) is not associated with inflammatory bowel disease susceptibility in East Anglia panel. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 967-971.	0.9	27
93	Immuno-inhibitory PD-L1 can be induced by a Peptidoglycan/NOD2 mediated pathway in primary monocytic cells and is deficient in Crohn's patients with homozygous NOD2 mutations.. <i>Clinical Immunology</i> , 2012, 143, 162-169.	1.4	27
94	The Genetics Universe of Crohn's Disease and Ulcerative Colitis. <i>Digestive Diseases</i> , 2012, 30, 78-81.	0.8	25
95	IBD BioResource: an open-access platform of 25,000 patients to accelerate research in Crohn's and Colitis. <i>Gut</i> , 2019, 68, 1537-1540.	6.1	25
96	Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of Interleukin 1 blockade in Acute Severe Colitis: the IASO trial. <i>BMJ Open</i> , 2019, 9, e023765.	0.8	25
97	Exclusion of Linkage of Crohn's Disease to Previously Reported Regions on Chromosomes 12, 7, and 3 in the Belgian Population Indicates Genetic Heterogeneity. <i>Inflammatory Bowel Diseases</i> , 2000, 6, 165-170.	0.9	24
98	DNA Methylation Analysis in the Intestinal Epithelium: Effect of Cell Separation on Gene Expression and Methylation Profile. <i>PLoS ONE</i> , 2013, 8, e55636.	1.1	24
99	Common pathways in Crohn's disease and other inflammatory diseases revealed by genomics. <i>Gut</i> , 2007, 56, 1489-1492.	6.1	22
100	The Impact of NOD2 Genetic Variants on the Gut Mycobiota in Crohn's Disease Patients in Remission and in Individuals Without Gastrointestinal Inflammation. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 800-812.	0.6	22
101	The use of Cyclosporin A in acute steroid-refractory ulcerative colitis: Long term outcomes. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 91-94.	0.6	21
102	A Method to Exploit the Structure of Genetic Ancestry Space to Enhance Case-Control Studies. <i>American Journal of Human Genetics</i> , 2016, 98, 857-868.	2.6	21
103	Ulcerative colitis and Crohn's disease: molecular genetics and clinical implications. <i>Expert Reviews in Molecular Medicine</i> , 2001, 3, 1-18.	1.6	20
104	Predicting the Individual Risk of Acute Severe Colitis at Diagnosis. <i>Journal of Crohn's and Colitis</i> , 2017, 11, jw159.	0.6	19
105	Autologous stem cell transplantation in refractory Crohn's disease: low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised controlled trial and observational follow up study. <i>BMC Gastroenterology</i> , 2019, 19, 82.	0.8	17
106	GWAS of stool frequency provides insights into gastrointestinal motility and irritable bowel syndrome. <i>Cell Genomics</i> , 2021, 1, 100069.	3.0	15
107	Genome-wide association scans identify multiple confirmed susceptibility loci for Crohn's disease: Lessons for study design. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 1554-1560.	0.9	14
108	Genome-wide rare copy number variation screening in ulcerative colitis identifies potential susceptibility loci. <i>BMC Medical Genetics</i> , 2016, 17, 26.	2.1	14

#	ARTICLE	IF	CITATIONS
109	The management of severe Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2001, 15, 563-573.	1.9	13
110	Clinical Trials [and Tribulations]: The Immediate Effects of COVID-19 on IBD Clinical Research Activity in the UK. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1769-1776.	0.6	13
111	Effectiveness and safety of vedolizumab in inflammatory bowel disease patients aged 60 and over: an observational multicenter UK experience. <i>Annals of Gastroenterology</i> , 2020, 33, 170-177.	0.4	13
112	Patients with perianal Crohn's fistulas experience delays in accessing anti-TNF therapy due to slow recognition, diagnosis and integration of specialist services: lessons learned from three referral centres. <i>Colorectal Disease</i> , 2018, 20, 797-803.	0.7	11
113	Mitochondrial neurogastrointestinal encephalopathy: a clinicopathological mimic of Crohn's disease. <i>BMC Gastroenterology</i> , 2019, 19, 11.	0.8	10
114	Randomized Trial of Ciprofloxacin Doxycycline and Hydroxychloroquine Versus Budesonide in Active Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2700-2711.	1.1	10
115	Genetics of Inflammatory Bowel Disease. A Personal View on Progress and Prospects. <i>Digestive Diseases</i> , 1998, 16, 370-374.	0.8	9
116	A Comparison of Outcomes for Adults and Children Undergoing Resection for Inflammatory Bowel Disease: Is There a Difference?. <i>ISRN Gastroenterology</i> , 2014, 2014, 1-4.	1.5	9
117	A systems genomics approach to uncover patient-specific pathogenic pathways and proteins in ulcerative colitis. <i>Nature Communications</i> , 2022, 13, 2299.	5.8	9
118	Symptom classification in irritable bowel syndrome as a guide to treatment. <i>Scandinavian Journal of Gastroenterology</i> , 2009, 44, 796-803.	0.6	8
119	Acetarsol Suppositories: Effective Treatment for Refractory Proctitis in a Cohort of Patients with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1011-1015.	1.1	8
120	Moving towards more patient-centred clinical trials in IBD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 673-674.	8.2	8
121	Mapping susceptibility loci in inflammatory bowel disease: why and how?. <i>Trends in Molecular Medicine</i> , 1997, 3, 546-553.	2.6	7
122	Ulcerative colitis is more strongly linked to chromosome 12 than Crohn's disease Reply. <i>Gut</i> , 2001, 49, 311-312.	6.1	5
123	A Crohn's Disease-associated IL2RA Enhancer Variant Determines the Balance of T Cell Immunity by Regulating Responsiveness to IL-2 Signalling. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 2054-2065.	0.6	5
124	Single-cell genomics for resolution of conserved bacterial genes and mobile genetic elements of the human intestinal microbiota using flow cytometry. <i>Gut Microbes</i> , 2022, 14, 2029673.	4.3	5
125	Molecular genetics of Crohn's disease: recent advances. <i>The European Journal of Surgery</i> , 2003, 164, 887-891.	1.0	3
126	The genetics of inflammatory bowel disease. <i>British Journal of Hospital Medicine</i> , 2003, 64, 599-602.	0.3	3

#	ARTICLE	IF	CITATIONS
127	Diverticular disease: picking pockets and population biobanks. <i>Gut</i> , 2019, 68, 769-770.	6.1	3
128	Rectovaginal Fistula in Crohn's Disease: When and How to Operate?. <i>Clinics in Colon and Rectal Surgery</i> , 2022, 35, 010-020.	0.5	3
129	Establishment of a validated central reading system for ileocolonoscopy in an academic setting. <i>Gut</i> , 2022, 71, 661-664.	6.1	3
130	A rare cause of duodenal stricture. <i>BMJ Case Reports</i> , 2011, 2011, bcr1020103379-bcr1020103379.	0.2	2
131	Microscopic colitis. <i>Medicine</i> , 2007, 35, 290-291.	0.2	1
132	Microscopic colitis. <i>Medicine</i> , 2011, 39, 237-238.	0.2	1
133	Personalised medicine and genetic prediction “are we there yet?”. <i>Clinical Medicine</i> , 2013, 13, s62-s64.	0.8	1
134	“High definition”™: not all it appears: Table 1. <i>Gut</i> , 2014, 63, 863.1-864.	6.1	1
135	Microscopic colitis. <i>Medicine</i> , 2019, 47, 388-390.	0.2	1
136	Two-Stage Genome-Wide Search in Inflammatory Bowel Disease: Strong Evidence for Susceptibility Loci on Chromosomes 3, 7 and 12. <i>Clinical Science</i> , 1997, 93, 18P-19P.	0.0	0
137	Genetics” Clinical and Therapeutic Applications. , 0, , 85-88.		0
138	Microscopic colitis. <i>Medicine</i> , 2015, 43, 291-292.	0.2	0
139	PWE-044”...The IBD bioresource: progressing from genetics to function and clinical translation in CD & UC. , 2018, , .		0
140	On the threshold of personalized medicine in inflammatory bowel disease: Next generation genetic predictors. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 5-6.	1.4	0
141	Debate session: So what causes inflammatory bowel disease? It's all in the genes. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 23-23.	1.4	0
142	Selectively targeting the gut in inflammatory bowel disease: Targeting integrins. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 26-26.	1.4	0
143	Genetic and Genomic Markers for Prognostication. , 2019, , 323-331.		0
144	The Inflammatory Bowel Disease (IBD) BioResource: an open-access platform of over 25,000 patients to accelerate research in Crohn's and Colitis. <i>Proceedings of the Nutrition Society</i> , 2020, 79, .	0.4	0

#	ARTICLE	IF	CITATIONS
145	P100â€¦Outcomes of a clinical psychology intervention in a UK IBD service. , 2021, , .		0
146	P156â€¦The inflammatory bowel disease (IBD) bioresource: focus on the inception cohort. , 2021, , .		0
147	Enhanced neoplasia detection in chronic ulcerative colitis: the ENDCaP-C diagnostic accuracy study. Efficacy and Mechanism Evaluation, 2021, 8, 1-88.	0.9	0
148	The Genetics of Crohnâ€™s Disease. , 2013, , 99-118.		0
149	IBD Genomic Risk Loci and Overlap with Other Inflammatory Diseases. , 2019, , 91-115.		0
150	IDDF2020-ABS-0183â€¦PROFILE trial: predicting outcomes for Crohnâ€™s disease using a molecular biomarker. , 2020, , .		0